Florent Le Prado

Associate

Paris + 33.1.56.59.38.04

Connect

Share

Florent Le Prado's practice includes all areas of private equity (venture capital, growth equity, and buyouts), M&A, and capital markets.

Florent represents emerging growth companies (listed and not listed), as well as the private equity and industrial investors that finance them, particularly in the software, energy transition, biotech/medtech, and fintech sectors, at every stage of development from their incorporation until their sale or IPO (initial public offering) and beyond.

Florent's recent experience includes representing Adikteev, Alizé Pharma, Cellectis, Contentsquare, CVE, Doctolib, Edgar Suites, Eurobio Scientific, Fintecture, Ivalua, Kyotherm, Lifen, Ouicar, Paylead, PlayPlay, Pretto, SuperSonic Imagine, TxCell, and Welcome to the Jungle. On the investor-side, he represented, among others, Alven Capital Partners, Bpifrance, ChapsVision, Crane Venture Partners, Creadev, Elaia Partners, Fluxys, IDIA Capital Investissement, New Alpha Asset Management, OCCTE, Open CNP, Portage Ventures, Serena Capital, Sofinnova, Temasek, and Tikehau Capital.

The transactions in which Florent has advised include the latest financing rounds of Cellectis, Contentsquare, CVE, CVE Biogaz, Edgar Suites, InnovaFeed, Kyotherm, Ivalua, John Cockerill Hydrogen, Melvan, Moon Surgical, Mooncard, OSS Ventures, and Welcome to the Jungle; several cross-border build-up acquisitions completed by Doctolib; the acquisitions of Heap by Contentsquare, eSoftThings by Lacroix Group, and Pipplet by ETS Global; the sales of Vialink to Signaturit and Heuritech to Luxurynsight; the leveraged buyouts (LBOs) of Brico Privé by Florac and Orolia by Eurazeo; the tender offers of SuperSonic Imagine, Coheris, TxCell, and Orolia; and the IPOs of Medincell and Pharnext.

Erfahrung

  • Fluxys participates in €116 million financing of John Cockerill HydrogenJones Day advised Fluxys as co-investor in connection with the €116 million financing of John Cockerill Hydrogen, a company specializing in green hydrogen solutions.
  • Consortium of investors leads Melvan's €25 million fundraisingJones Day advised a consortium of investors led by Bpifrance, IDIA Capital Investissement, a pool of other investors from the Crédit Agricole group, and OCCTE, in connection with the €25 million financing of Melvan, a French producer and developer of multi-technology renewable energies.
  • Serena Capital and Crane Venture Partners lead $9 million seed financing of pyannoteAIJones Day advised Serena Capital and Crane Venture Partners in connection with the $9 million seed financing of pyannoteAI, the first language-agnostic speaker intelligence platform for developers.
  • CVE Biogaz raises €70 millionJones Day advised CVE Biogaz, a major player in organic matter recovery and methanization in France, in raising €70 million from BNP Paribas Asset Management, accelerating its development and strengthening its position in the European methanization market.
  • Kyotherm raises €300 millionJones Day advised Kyotherm, a co-developer and financer of renewable heat and energy efficiency projects, in connection with its €300 million financing led by InfraVia Capital Partners and existing investor, Andera Partners.
  • Tikehau Capital co-leads €8.5 million fundraising for OSS VenturesJones Day advised Tikehau Capital in connection with the €8.5 million fundraising of OSS Ventures, a leading industrial start-up studio in France, for propelling the future of operations, also led by France 2030's French Tech Accélération 2 fund (Bpifrance) and Etablissements Peugeot.
  • Doctolib acquires Aaron.aiJones Day advised Doctolib, the leading healthtech company in Europe, in its acquisition of the Berlin company Aaron.ai, the current market leader in Germany for AI-based telephone assistance solutions for medical practices, relieving doctors and practice staff of answering telephone calls and offering patients telephone access to doctors' practices around the clock.
  • Cellectis and AstraZeneca enter into research collaboration and agree on equity investment of up to $220 million by AstraZenecaJones Day advised Cellectis in connection with the joint research collaboration agreement entered into with AstraZeneca and initial equity investment by AstraZeneca into Cellectis of $80 million.
  • Radial Equity acquires Moss Motors and Rimmer BrosJones Day advised Radial Equity Partners in the acquisition and financing of Moss Motors, a U.S.-headquartered aftermarket supplier of parts for British cars, and Rimmer Bros, a UK-based supplier of replacement parts for UK marque vehicles.
  • VIALINK sold to SignaturitJones Day advised VIALINK in the sale of the company to PSG-backed Signaturit.
  • Serena invests in KotzillaJones Day advised Serena Capital in the $2 million seed financing of Kotzilla, a French company engaged in the development and marketing of an application monitoring developer platform.
  • Caisse des Depots et Consignation invests in European submarine cable MedloopJones Day advised Caisse des Depots et Consignation ("CDC") with its investment in Fiberspirit, a SPV owning and operating the European submarine cable system managed by Medloop connecting France, Spain, and Italy.
  • NANO Corp raises €4.2 million in seed financingJones Day advised NANO Corp, a cybersecurity firm providing software-based network detection and response (NDR) solutions, in connection with its €4.2 million seed financing, led by G+D Ventures.
  • Contentsquare acquires HeapJones Day acted as French counsel to Contentsquare in the acquisition of Heap, a leading U.S. product analytics platform.
  • DJUST raises €12 million in Series A financingJones Day represented DJUST, a B2B eCommerce SaaS platform, in connection with its €12 million Series A growth funding led by New Enterprise Associates, Inc. (NEA), with additional participation from Elaia Partners.
  • Sofinnova and NVentures co-lead $55.4 million financing of Moon SurgicalJones Day advised Sofinnova Partners (through Sofinnova Capital Strategy) and NVentures (NVIDIA's venture capital arm) as lead investors in connection with the $55.4 million financing of Moon Surgical, a French-American pioneer in collaborative robotics.
  • CVE raises €100 million from ICG InfraJones Day advised CVE, a France-based independent producer of renewable energy across multiple countries and sources of power, in connection with its €100 million financing round led by Intermediate Capital Group plc, a global alternative asset manager, through its infrastructure investment arm (ICG Infra).
  • Portage and Orange Ventures lead €37 million Series C financing of MooncardJones Day advised Portage and Orange Ventures as lead investors in connection with the €37 million Series C financing of Mooncard, the French leader in the automation of corporate spend, in which historical investors Aglaé Ventures, BlackFin Capital Partners, Partech Partners and RAISE Ventures also participated.
  • Welcome to the Jungle raises €50 million in Series C financingJones Day represented Welcome to the Jungle, a company that develops and operates a recruitment and employer branding solution, in connection with its €50 million Series C financing led by Cipio Partners and Blisce alongside new investors, Kostogri, Groupe ADP, and Raise Sherpas, and existing investors, Revaia, XAnge, and Bpifrance (Digital Venture).
  • Fintecture raises €26 million in Series A financingJones Day advised Fintecture, a pioneering next-gen B2B payment platform, in connection with its €26 million Series A financing led by new investors Eurazeo, RTP Global, HEC Ventures, Allianz Trade with existing investors Target Global, Samaipata and Business Angels also participating.
    •

    Bitte beachten Sie vor dem Versenden:

    Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.